Novartis
NEWS
The Francis Crick Institute and the Latvian Institute of Organic Synthesis developed a new compound that blocks the life cycle of the mosquito-borne parasite that causes malaria.
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
The high court’s decision will prevent Sandoz from launching its biosimilar to Amgen’s blockbuster rheumatoid arthritis drug.
The robust $77 million Series A was led by Octagon Capital and the leadership and research team behind the original Vedere Bio.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 4, 2021.
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
Work-at-home arrangements created to respond to the COVID-19 pandemic have forced numerous companies in most sectors to reevaluate their work deals. This has also resulted in rethinking site locations and real estate needs. Here’s a look.
Novartis AG Chief Executive Officer Vas Narasimhan believes that the hybrid of remote and on-site office work is the future.
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
JOBS
IN THE PRESS
